Digitale Bibliotheek
Sluiten Bladeren door artikelen uit een tijdschrift
     Tijdschrift beschrijving
       Alle jaargangen van het bijbehorende tijdschrift
         Alle afleveringen van het bijbehorende jaargang
                                       Alle artikelen van de bijbehorende aflevering
 
                             27 gevonden resultaten
nr titel auteur tijdschrift jaar jaarg. afl. pagina('s) type
1 Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE Mamounas, E.P.

32 8 p. 1005-1014
artikel
2 A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793) Bellone, S.

32 8 p. 1045-1046
artikel
3 A randomized phase III trial comparing trabectedin to best supportive care in patients with pre-treated soft tissue sarcoma: T-SAR, a French Sarcoma Group trial Le Cesne, A.

32 8 p. 1034-1044
artikel
4 Bringing safe and effective therapies to premenopausal women with breast cancer: efforts to broaden eligibility criteria Gao, J.J.

32 8 p. 950-953
artikel
5 Checkpoint inhibition: protecting against or predisposing for second primary tumors? Reply to the Letter to the Editor ‘Checkpoint inhibition: protecting against or predisposing for second primary tumors?’ by K. P. M. Suijkerbuijk, A. M. May and M. J. M. van Eijs Heudel, P.

32 8 p. 1055-1057
artikel
6 Corrigendum to ‘Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q' Jhaveri, K.L.

32 8 p. 1068
artikel
7 Corrigendum to ‘The forefront of ovarian cancer therapy: update on PARP inhibitors' Mirza, M.R.

32 8 p. 1066-1067
artikel
8 Editorial Board
32 8 p. iii
artikel
9 Erratum to ‘Germline-focussed analysis of tumour-only sequencing: recommendations from the ESMO Precision Medicine Working Group’ Mandelker, D.

32 8 p. 1069-1071
artikel
10 First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis Emens, L.A.

32 8 p. 983-993
artikel
11 Impaired immunogenicity of BNT162b2 anti-SARS-CoV-2 vaccine in patients treated for solid tumors Barrière, J.

32 8 p. 1053-1055
artikel
12 ‘IMpassionate conflicts’ in immunotherapy trials for metastatic triple-negative breast cancer Voorwerk, L.

32 8 p. 947-949
artikel
13 Important news on nutritional support in cancer patients – but some EFFORT is still ahead Arends, J.

32 8 p. 954-956
artikel
14 Management of BRAF-mutant metastatic colorectal cancer: a review of treatment options and evidence-based guidelines Grothey, A.

32 8 p. 959-967
artikel
15 Nutritional support during the hospital stay reduces mortality in patients with different types of cancers: secondary analysis of a prospective randomized trial Bargetzi, L.

32 8 p. 1025-1033
artikel
16 Oncolytic virus in gliomas: a review of human clinical investigations Carpenter, A.B.

32 8 p. 968-982
artikel
17 PARP inhibitors and newly second primary malignancies in cancer patients: a systematic review and safety meta-analysis of placebo randomized controlled trials Morice, P.-M.

32 8 p. 1048-1050
artikel
18 Prevalence of ctDNA in early screen-detected breast cancers using highly sensitive and specific dual molecular barcoded personalised mutation assays Page, K.

32 8 p. 1057-1060
artikel
19 Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer Miles, D.

32 8 p. 994-1004
artikel
20 Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival Slamon, D.J.

32 8 p. 1015-1024
artikel
21 Table of Contents
32 8 p. i-ii
artikel
22 The positive effect of immune checkpoint inhibitor-induced thyroiditis on overall survival accounting for immortal time bias: a retrospective cohort study of 6596 patients Street, S.

32 8 p. 1050-1051
artikel
23 Therapy-related myeloid neoplasms following treatment with PARP inhibitors: new molecular insights Martin, J.E.

32 8 p. 1046-1048
artikel
24 Trabectedin: useful in leiomyosarcoma and liposarcoma, but less so in other soft tissue sarcomas Schuetze, S.

32 8 p. 957-958
artikel
25 VP6-2021: IMpassion050: A phase III study of neoadjuvant atezolizumab + pertuzumab + trastuzumab + chemotherapy (neoadj A + PH + CT) in high-risk, HER2-positive early breast cancer (EBC) Huober, J.

32 8 p. 1061-1062
artikel
26 VP5-2021: IMpower133: Gene expression (GE) analysis in long-term survivors (LTS) with ES-SCLC treated with first-line carboplatin and etoposide (CE) ± atezolizumab (atezo) Liu, S.V.

32 8 p. 1063-1065
artikel
27 Weak immunogenicity after a single dose of SARS-CoV-2 mRNA vaccine in treated cancer patients Palich, R.

32 8 p. 1051-1053
artikel
                             27 gevonden resultaten
 
 Koninklijke Bibliotheek - Nationale Bibliotheek van Nederland